Finance

Beta
Lists
524372:BOM
Orchid Pharma Ltd
₹846.60
+1.47%
(+12.25) 1D
Jun 5, 3:30:00 PM GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for 524372...
Open
₹840.50
High
₹846.60
Low
₹827.30
Mkt. cap
43.11B
Avg. vol.
4.46K
Volume
1.46K
52-wk high
₹898.45
52-wk low
₹471.30
No. of employees
736
Open
₹840.50
High
₹846.60
Low
₹827.30
Mkt. cap
43.11B
Avg. vol.
4.46K
Volume
1.46K
52-wk high
₹898.45
52-wk low
₹471.30
No. of employees
736
News stories
From sources across the web
Profile
Orchid Pharma Limited is an Indian pharmaceutical company based in Chennai. It was founded by Kailasam Raghavendra Rao on 1 July 1992. Orchid Pharma is the only pharma company in India to have discovered a New Drug Enmetazobactam which is now approved in United States, Europe and India. Wikipedia
About Orchid Pharma Ltd
CEO-
Employees736
Founded1992
Headquarters-
SectorPharmaceutical industry
Websiteorchidpharma.com
Previous reportsAll values in INR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in INR
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
1.73B
1.94B
2.07B
2.38B
Cost of goods sold
988.65M
1.33B
1.43B
1.51B
Cost of revenue
988.65M
1.33B
1.43B
1.51B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
216.13M
248.51M
241.28M
208.78M
Operating expense
685.42M
713.95M
715.86M
682.54M
Total operating expenses
1.67B
2.04B
2.15B
2.20B
Operating income
55.21M
-103.77M
-74.65M
179.97M
Other non operating income
114.48M
107.74M
56.09M
73.42M
EBT including unusual items
149.11M
-57.24M
-126.14M
237.82M
EBT excluding unusual items
149.11M
-57.24M
-55.01M
232.43M
Income tax expense
-
-
-
17.00K
Effective tax rate
-
-
-
0.01%
Other operating expenses
382.75M
376.43M
384.29M
385.08M
Net income
149.11M
-57.24M
-126.14M
237.80M
Net profit margin
8.62%
-2.96%
-6.09%
10.01%
Earnings per share
-
-1.13
-1.08
4.58
Interest and investment income
-
-
-
-
Interest expense
-32.58M
-37.32M
-31.78M
-30.91M
Net interest expenses
-32.58M
-37.32M
-31.78M
-30.91M
Depreciation and amortization charges
86.54M
89.01M
90.29M
88.68M
EBITDA
141.58M
-15.99M
10.45M
268.60M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer